These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36327946)

  • 1. Impact of Omalizumab on Anaphylaxis in Patients Treated for Chronic Urticaria.
    Song X; Liu B; Yu M; Liao S; Luan T; Li C; Zhao Z
    Int Arch Allergy Immunol; 2023; 184(2):199-201. PubMed ID: 36327946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
    Altrichter S; Staubach P; Pasha M; Singh B; Chang AT; Bernstein JA; Rasmussen HS; Siebenhaar F; Maurer M
    J Allergy Clin Immunol; 2022 May; 149(5):1683-1690.e7. PubMed ID: 34954198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
    Kocatürk E; Başkan EB; Küçük ÖS; Özdemir M; Örnek S; Can PK; Haşal E; Engin B; Atakan N; Alpsoy E
    An Bras Dermatol; 2022; 97(5):592-600. PubMed ID: 35853771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
    ; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
    Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study.
    Cakmak ME
    Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
    Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
    Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Giordano-Labadie F; Becherel PA; Pralong P; Outtas O; Ruer-Mulard M; Berard F; Greco M; Lacour JP; Debons-Peyroutet M; Pelvet B; Lamirand A; Guillet G
    Eur J Dermatol; 2021 Apr; 31(2):217-224. PubMed ID: 34001470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the long-term economic burden of omalizumab on patients with chronic spontaneous urticaria.
    Matsubara D; Takahagi S; Saito R; Kamegashira A; Tanaka A; Hide M
    J Dermatol; 2021 Jan; 48(1):56-63. PubMed ID: 33029864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of at least 1-year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria.
    Su O; Bahali AG; Onsun N
    Dermatol Ther; 2020 Nov; 33(6):e14192. PubMed ID: 32790183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
    Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
    Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed Pressure Urticaria: Clinical and Diagnostic Features and Response to Omalizumab.
    Veleiro-Pérez B; Alba-Muñoz J; Pérez-Quintero O; Rodríguez RL; Calvín-Lamas M; Parra-Arrondo A
    Int Arch Allergy Immunol; 2022; 183(10):1089-1094. PubMed ID: 35609554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
    Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
    Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
    Yuan W; Hu S; Li M; Yang L; Liu L; Zheng M; Guo Z; Song Z; Zhang C; Diao Q; Xu J; Richard A; Patwardhan M; Lyu T; Uddin A; Fogel R; Ligueros-Saylan M; Zheng J
    Dermatol Ther; 2022 Apr; 35(4):e15303. PubMed ID: 34984792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A patient-oriented approach to long-term use of omalizumab in chronic spontaneous urticaria.
    Ornek S; Kocaturk E
    Cutan Ocul Toxicol; 2021 Dec; 40(4):305-311. PubMed ID: 34212792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Related to Omalizumab Drug Survival and Treatment Responses in Chronic Urticaria.
    Hasal E; Bulbul Baskan E; Yazici S; Aydogan K; Saricaoglu H
    Int Arch Allergy Immunol; 2022; 183(11):1198-1208. PubMed ID: 36037806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
    Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
    Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
    Salman A; Ergun T; Gimenez-Arnau AM
    J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
    Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
    J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.